|
Jul 22
|
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results
|
|
Jul 21
|
This Healthcare Stock's Revolutionary Drug Could Make Early Investors Rich
|
|
Jul 17
|
Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings
|
|
Jul 13
|
China Biotech’s Stunning Advance Is Changing the World’s Drug Pipeline
|
|
Jul 10
|
Summit Therapeutics (SMMT) Jumps 7.6% on Reports of $15-Billion AstraZeneca Deal
|
|
Jul 9
|
Summit, AstraZeneca (AZN) in Advanced Talks Over $15 billion Oncology Licensing Deal
|
|
Jul 2
|
Summit Therapeutics (SMMT) Rated Buy on Ivonescimab’s Cancer-Fighting Potential
|
|
Jun 30
|
Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors
|
|
Jun 25
|
H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target
|
|
Jun 5
|
Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
|
|
Jun 5
|
Why Summit Therapeutics Inc. (SMMT) Crashed On Wednesday
|
|
May 9
|
Summit Therapeutics Inc. (SMMT): Among the Best Cancer Stocks to Invest in for Long-Term Gain
|
|
May 7
|
Can Summit Therapeutics Stock Double Your Money?
|
|
May 6
|
Wall Street Analysts Predict a 33.4% Upside in Summit Therapeutics (SMMT): Here's What You Should Know
|
|
May 4
|
Why Summit Therapeutics Inc. (SMMT) Soared Last Week
|
|
Apr 26
|
Akeso survival data for ivonescimab misses expectations, STAT says
|
|
Apr 25
|
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today
|
|
Apr 25
|
Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China
|
|
Apr 24
|
Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025
|
|
Apr 24
|
Akeso and Summit notch another Phase III win with their Keytruda competitor
|